www.r-pharm.com

R-PHARM – COMPANY OVERVIEWJune, 2017

Jefferies 2017

Health Care Conference

June 9, 2017

Demetrios Kydonieus, President & CBO

1

R-Pharm Key Facts

Established in 2001, 100% private.

The leading Russian vertically integrated

specialty care pharmaceutical company.

Products from a broad range of

specialty/hospital care therapeutic areas.

Preferred partner for global Pharma

leaders.

3,500+ employees at 50+ branches.

Presence in 9 countries.

RUR 77,6+ bn revenue in 2015.

Research &

Development

Manufacturing

Marketing & Sales

Distribution

2

Management Team

Ivan Semenov

VP HR and OD

Kathrin Abelein

VP Quality

Tuygan Goker

President

TR-Pharm

Mikhail Samsonov

Chief Medical Officer

Yan Lavrovsky

CSO, CEO

R-Pharm Overseas

Vasily Ignatiev

Chief Executive Officer

Alexey Repik

Chairman, Founder

Mark Pavao

President and CEO

R-Pharm US LLC

Valeria Povolotsky

VP – Global Partnering

Andrey Smirnov

Chief Financial Officer

Holger Weyhers

Managing Director

R-Pharm Germany

Demetrios Kydonieus

President and CBO

R-Pharm US LLC

Alexey Ordzhonikidze

VP External Affairs

Chris Posner

VP Immunology

Valery Pereletov

VP – Commercial Affairs

3

Solid Growth Despite Market Volatility

R-Pharm

Others

2015

25%

75%

31.3 39.3 41.946.1

60.8

77.6

30 29.325.5

21.3 24.3

31.8

0

1016.4

24.836.5

45.8

2010 2011 2012 2013 2014 2015

R-Pharm sales volume

Sales volume

Distribution

R&D, manufacturing and S&M

Billion

Rubles

Hospital & Reimbursement

Segment (Russia)

The leading position

in public procurement

Note: R-Pharm data

Strong double digit sales growth including 2015, despite slower domestic market growth.

Successful transformation from distribution to a fully vertically integrated specialty pharma.

Integration strategy plus portfolio transformation significantly increased profitability.

4

Functional/Therapeutic Areas

• R&D

• Manufacturing

• Distribution

• Market Access

• Promotion

• Oncology

• Antivirals

• Antibiotics

• Neurology

• Immunology

• Vaccines

• Diabetes

• Acute care cardiology

• Orphan diseases

5

6

Oncology

Avastin

Beyodym

Herceptin

Kadcyla

Keytruda

Sprycel

Tarceva

Xeloda

HIV / AIDS / Hepatitis

treatment

Baraclude

Daklinza

Isentress

Kaletra

Reyataz

Sebivo

Viekira Pak

Antibiotics

Cubicin

Invanz

Spectracef

Tienam

Vibativ

HumiraAnti-inflammatory

Other Aubagio

De-Nol

Duodopa

Humalog

Prograf

Therapeutic area Partner Company Products

Over 70 In-Licensed / Co-Promoted Products

7

R-Pharm value proposition Current partners

Unmatched commercialization

power in Russia, EEU and CIS,

and beyond

Compliant partner with strong

reputation.

Very experienced commercial

groups in Russia, EEU & CIS,

Turkey/MENA and US driving

partnering deals.

Highly professional Development

& Regulatory, with fast track

opportunities.

State of the art manufacturing

(Solid forms, Sterile F&F,

Biologics, API).

Develo

pm

en

tM

an

ufa

ctu

rin

gP

rom

oti

on

R-Pharm Partnering Strengths

Three Strategic Pillars

Continue the pathway of transformation.

Invest in new R&D projects.

Pursue leading edge in manufacturing in Russia.

Create new therapeutic area specific partnerships/JVs with

multinational players.

Invest in a healthy & robust product pipeline.

13 in-licensed and 7 own attractive products currently under

development – 5 currently in registration.

Strengthening of

the fully integrated

value-chain in Russia/EEU/CIS

Geographical expansion

to realize full commercial

potential

Investment in innovative

product portfolio

Build broader geographic footprint – R-Pharm today present

in 9 countries and further expansion planned.

Grow outside Russia to realize full product potential.

Become closer to existing & new partners for new business

opportunities.

Become the first fully integrated Russian

pharma player with global footprint

1

2

3

8

Robust Pipeline

R-Pharm

Pipeline

In-licensed

pipeline

Cell line &process

developmentPre-Clinical

Clinicalstudies

Filing /registration ProductTA

Oncology

Anti-infective

&

antiviral

Anti-

inflammatory

Others

RPH 001

RPH 002

RPH 203

RPH 120

Olokizumab

RPH 104

RPH 007

Remimazolam

Narlaprevir

Nemonoxacin

Odelepran

SCY 078

Fimasartan

Cefilavancin

Radotinib

Imidafenacin

Ixabepilone

ONC1-0013B

Marketed

Telavancin Marketed

9

Selected Pipeline Highlights

Product Description/Status

Olokizumab

RPH-203

Globally patented osteoprotegrin-IgG1 (Fc) fusion protein –

RANKL inhibitor.

Treatment for tumor-related bone lytic lesions, giant cell bone

tumors, etc.

Phase I completed, Phase II clinical trial initiated in Oct 2015.

RPH-104

Globally patented novel recombinant heterodimer nanoprotein.

Inhibits IL-1β/IL-1F2-induced signaling.

FIH study initiated in Jan 2016.

Target indications: FMF, Behcet’s disease.

Globally licensed anti-IL-6 MAB for RA and other indications.

Solid and sustained efficacy in difficult to treat subgroups (anti-

TNF-NRs) in phase II.

Completed FDA (CMC, EOP2) and EMA (SAWP) consultations.

International phase III program initiated in May 2016.

10

Geographic Expansion

2013 majority

owned affiliate set

up in Turkey

R-Pharm with local activities

2010 R&D

partnership in

India established

2013 launch of

research collaboration

in Japan

2014 acquisition of a

manufacturing

asset in Germany

2014 R-Pharm US LLC

est. in the US

2014 API and F&F

site in Turkey

being designed

2011 R&D and BD

company est. in the US

2014 Commercial

entity established

in UAE

11

R-Pharm US: Specialty

BioPharma Business for the Americas

Key Facts:

• Founded in 2014 in Princeton, NJ.

• Focus: Oncology, Immunology and Specialty Diseases.

• Ixempra for aggressive metastatic or locally advanced breast cancer

acquired from BMS, (global rights).

• Fully integrated commercialization team over 50 FTEs.

• 2016 sales estimated at $45M.

Strategy:

• Phase 1: Acquire underserved medicines and maximize their potential

through efficient, innovative commercialization.

• Phase 2: Leverage commercialization infrastructure to successfully

launch R-Pharm JSC developed medicines.

12

R-Pharm US Portfolio 13

Ixempra*

• Acquired from Bristol-Myers Squibb in 2015

• Indicated for metastatic breast cancer

• Fully dedicated commercialization in USA

• Distribution partners for 11 ex-US markets

Episil*

• Licensed from Camurus AB in 2016

• Fully dedicated commercialization in USA

• Indicated for oral mucositis

Zuplenz* and Oravig*

• 2016 US co-promotion with Midatech

• Supportive care brands complementary to

Ixempra and Episil

* See product website for full prescribing information

www.ixempra.com

www.episilusa.com

www.zuplenz.com

www.oravig.com

Three Strategic Pillars

Strengthening of

the fully integrated

value-chain in Russia/EEU/CIS

Geographical expansion

to realize full commercial

potential

Investment in innovative

product portfolio

Become the first fully integrated Russian

pharma player with global footprint

14

Thank you!

Demetrios Kydonieus,

President & CBO R-Pharm US

demetrios.kydonieus@rpharm-us.com

15